A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

taladegib

hedgehog pathway inhibitor dosed once daily

DRUG

placebo

identical tablets to the experimental arm with no active ingredient

Trial Locations (24)

1871

Research Site, Liverpool

3128

Research Site, Box Hill

3168

Research Site, Clayton

4217

Research Site, Benowa

14080

Research Site, Mexico City

15200

Research Site, Kota Bharu

31203

Research Site, Chihuahua City

53000

Research Site, Kuala Lumpur

56000

Research Sire, Kuala Lumpur

59100

Research Site, Kuala Lumpur

64060

Research Site, Monterrey

64718

Research Site, Monterrey

66465

Research Site, San Nicolás de los Garza

68000

Research Site, Oaxaca City

68100

Research Site, Batu Caves

72180

Research Site, Puebla City

V5Z 1M9

Research Site, Vancouver

J1H 5N4

Research Site, Sherbrooke

03100

Research Site, Mexico City

Unknown

Research Site (Namdong District), Incheon

Research Site (Bundang District), Seongnam

Research Site (Gangnam District), Seoul

Research Site (Seongbuk District), Seoul

Research Site (Songpa District), Seoul

Sponsors
All Listed Sponsors
lead

Endeavor Biomedicines, Inc.

INDUSTRY

NCT04968574 - A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter